Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: A clinical survey of 5 cases in Catania, Italy

Journal of Clinical Virology

Volumn 52, Issue 4, 2011, Pages 284-287

  Montineri, Arturo ^a   Nigro, Luciano ^b   La Rosa, Rosario ^a   Iacobello, Carmelo ^a   Larocca, Licia ^a   Cappello, Elisa ^b   Fiumara, Paolo Fabio ^b   Di Raimondo, Francesco ^b   Fatuzzo, Filippo ^a  

^a Medical Specialties Unit of Infectious Diseases   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

HBV reactivation; Lamivudine; Telbivudine; Tenofovir; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; BUSULFAN; FLUDARABINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISOLONE; RITUXIMAB; TELBIVUDINE; TENOFOVIR; THYMOCYTE ANTIBODY; VIRUS DNA;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ITALY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; ITALY; MALE; MIDDLE AGED; VIRUS ACTIVATION;

EID: 82755189483     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.08.007     Document Type: Article

References (34)

1. Ganem D., Prince A.M. Hepatitis B infection-natural history and clinical consequences. N Engl J Med 2004, 350:1118-1129.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
3. Pollicino T., Belloni L., Raffa G., Pediconi N., Squadrito G., Raimondo G., et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA Bound H3 and H4 histonnes. Gastroenterology 2006, 130:823-837.
4. Rehermann B., Ferrari C., Pasquinelli C., Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996, 2:1104-1108.
5. Leung N.W.Y., Tam J.S.L., Lau G.T.C., Leung T.W.T., Lau W.Y., Li A.K.C. Hepatitis B virus DNA in peripheral blood leucocytes-a comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994, 73:1143-1148.
6. Raimondo G., Navarra G., Mondello S., Costantino L., Colloredo G., Cucinotta E., et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008, 48:743-746.
7. Marzano A., Angelucci E., Andreone P., Brunetto M., Bruno M., Burra P., et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39:397-408.
8. Lok A.S., Lai C.L., Wu P.C., Leung E.K., Lam T.S. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B infection. Gastroenterology 1987, 92:1839-1843.
9. Takai S., Tsurumi H., Ando K., Kasahara S., Sawada M., Yamada T., et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005, 74:158-165.
10. Marcucci F., Mele A., Spada E., Candido A., Bianco E., Pulsoni A., et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006, 91:554-557.
11. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136:699-712.
12. Lok A.S.F., Liang R.H.S., Chiu E.K.W., Wong K.L., Chan T.K., Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy Report of a prospective study. Gastroenterology 1991, 100:182-188.
13. Nakamura Y., Motokura T., Fujita A., Yamashita T., Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies survey in Japan 1987-1991. Cancer 1996, 78:2210-2215.
14. Ling R., Lau G.K.K., Kwong Y.L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999, 17:394-398.
15. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209-220.
16. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714-1722.
17. Hui C.K., Lau G.K. The present and future therapy for chronic hepatitis B infection. Semin Liver Dis 2006, 26:192-197.
18. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
19. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962.
20. Kobayashi M., Suzuki F., Akuta N., Hosaka T., Sezaki H., Yatsuji H., et al. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol 2007, 79:1472-1477.
21. Woo G., Tomlinson G., Nishikawa Y., Kowgier M., Sherman M., Wong D.K., et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analysis. Gastroenterology 2010, 139:1218-1229.
22. Montineri A., Nigro L., Chiarenza A., La rocca L., La Rosa R., Iacobello C., et al. Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non Hodgkin lymphoma. Leuk Lymphoma 2010, 51:554-557.
23. Christopeit M., Weber T., Abendroth J., Dollinger M., Lubbert C., Oehme A., et al. HBs seroconversion in a patient with epatiti B treated with entecavir during immunosuppression against severe bronchilitis obliterano in the course of chronic graft versus host disease. J Med Virol 2010, 48:218-219.
24. Marusawa H., Uemoto S., Hijikata M. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000, 31:488-495.
25. Cabrerizo M., Bartolome J., Caramelo C. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000, 32:116-123.
26. Guidotti L.G., Chisari F. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996, 8:478-483.
27. Chisari F. Perspectives series: host/pathogen interactions Cytotoxic T cells and viral. J Clin Invest 1997, 99:1472-1477.
28. Maini M.K., Bertoletti A. How can the cellular immune response control hepatitis B virus replication?. J Viral Hepat 2000, 7:321-326.
29. Lalazar G., Rund D., Shouval D. Screening prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136:699-712.
30. Tsutsumi Y., Shigematsu A., Hashino S., Tanaka J., Chiba K., Masauzi N., et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's Lymphoma in Hokkaido. Ann Hematol 2009, 88:375-377.
31. Seth P., Alrajhi A.A., Kagevi I., Chaudhary M.A., Colcol E., Sahovich E., et al. Hepatitis B virus reactivation with clinical flare in allogenic stem cell transplant with chronic graft-versus host disease. Bone Marrow Transplant 2002, 30:189-194.
32. Lau G.K.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
33. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
34. Nunez M., Ramos B., Diaz-Pollan B., Camino N., Martins-Carbonero L., Barreiro P., et al. Virological outcome of chronic hepatitis B virus in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses 2006, 22:842-848.